Scholar Rock Holding (SRRK) Enterprise Value (2017 - 2026)
Scholar Rock Holding's (SRRK) quarterly Enterprise Value came in at -$479.9 million in Q1 2026, down 31.72% year-on-year from -$702.9 million in Q1 2025, and down 30.57% quarter-over-quarter from -$367.6 million in Q4 2025.
Scholar Rock Holding (SRRK) Enterprise Value (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Enterprise Value history runs 10 years deep, the most recent figure standing at -$479.9 million for Q1 2026.
- On a quarterly basis, Enterprise Value fell 31.72% year-over-year to -$479.9 million in Q1 2026; TTM through Mar 2026 was -$479.9 million, a 31.72% decrease from a year earlier, with the FY2025 full-year figure at -$367.6 million, up 15.94% from the prior year.
- Enterprise Value fell to -$479.9 million in Q1 2026 per SRRK's latest filing, from -$367.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$139.1 million in Q3 2024 and bottomed at -$479.9 million in Q1 2026.
- The 5-year median for Enterprise Value is -$295.0 million (2025), against an average of -$302.6 million.
- Across the five-year window, Enterprise Value soared 36.39% in 2024 and plunged 165.8% in 2025, its largest moves.
- Year by year, Enterprise Value stood at -$315.4 million in 2022, then climbed by 11.23% to -$279.9 million in 2023, then plunged by 56.21% to -$437.3 million in 2024, then increased by 15.94% to -$367.6 million in 2025, then slumped by 30.57% to -$479.9 million in 2026.
- Per Business Quant, the three latest SRRK Enterprise Value figures stand at -$479.9 million (Q1 2026), -$367.6 million (Q4 2025), and -$369.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - | -479.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -479.94 Mn |
| Dec 31, 2025 | -367.56 Mn |
| Sep 30, 2025 | -369.63 Mn |
| Jun 30, 2025 | -295.01 Mn |
| Mar 31, 2025 | -364.38 Mn |
| Dec 31, 2024 | -437.28 Mn |
| Sep 30, 2024 | -139.07 Mn |
| Jun 30, 2024 | -190.49 Mn |
| Mar 31, 2024 | -238.43 Mn |
| Dec 31, 2023 | -279.94 Mn |
| Sep 30, 2023 | -218.64 Mn |
| Jun 30, 2023 | -248.73 Mn |
| Mar 31, 2023 | -275.28 Mn |
| Dec 31, 2022 | -315.36 Mn |
| Sep 30, 2022 | -343.66 Mn |
| Jun 30, 2022 | -370.69 Mn |
| Mar 31, 2022 | -210.21 Mn |
| Dec 31, 2021 | -252.99 Mn |
| Sep 30, 2021 | -246.44 Mn |
| Jun 30, 2021 | -282.22 Mn |